No insider purchase over the last 90 days. The latest was filed 19 Feb 2026.
Every trade that managers of Camurus AB disclose to Finansinspektionen is tracked on this page. The company sits in the Health Care sector and is based in Lund, Sweden. It was founded in 1991. The last twelve months, up to 18 October 2026, brought 4 filings signed by 4 insiders.
The record shows 2 purchases on the open market worth €63k, made by 2 insiders, against 1 sale worth €279k by 1 insider. Taken together, the sales exceed the purchases by €216k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 2 board members. Biggest ticket of the year: €279k, sold by Richard Jameson and made public on 10 August 2026 (0.0086% of market cap).
Compared with its exchange (885 companies, median 7 filings), a count of 4 filings is below the norm. Since 2021, the database holds 2 purchases and 7 sales by insiders of the company.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 19 February 2026, 241 days ago. The median gap between a trade and its publication by Finansinspektionen is 1 day. The legal deadline for notifying a trade is three business days (MAR article 19).
For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Camurus AB Strong Buy (bullish), based on 8 analysts. Average price target: SEK 797.50.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
21 of 21 declarations
Camurus AB is a Swedish biopharmaceutical company focused on developing innovative treatments for chronic diseases. It is listed on the Stockholm Stock Exchange (XSTO).
Headquarters: Lund, Sweden · Founded: 1991 · Wikipedia article
Source: Wikidata (CC0).